Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Telang, Sucheta ^a   Nelson, Kristin K ^a   Siow, Deanna L ^a   Yalcin, Abdullah ^a   Thornburg, Joshua M ^a   Imbert Fernandez, Yoannis ^a   Klarer, Alden C ^a   Farghaly, Hanan ^b   Clem, Brian F ^a   Eaton, John W ^a   Chesney, Jason ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Electron transport chain; Glycolysis; Mitochondria; Oncogene; Tricarboxylic acid cycle

Indexed keywords

CYTOCHROME C OXIDASE; K RAS PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; EUKARYOTE; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; STEADY STATE;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; ELECTRON TRANSPORT COMPLEX IV; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OXYGEN CONSUMPTION; RAS PROTEINS; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865220978     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-60     Document Type: Article

References (31)

1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
2. Kole HK, Resnick RJ, Van Doren M, Racker E. Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Arch Biochem Biophys 1991, 286:586-590. 10.1016/0003-9861(91)90084-V, 1832835.
3. Racker E, Resnick RJ, Feldman R. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci U S A 1985, 82:3535-3538. 10.1073/pnas.82.11.3535, 397819, 3858838.
4. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005, 102:5992-5997. 10.1073/pnas.0502267102, 1087961, 15840712.
5. Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J. The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 2007, 6:77. 10.1186/1476-4598-6-77, 2222650, 18053146.
6. Chesney J, Telang S. Regulation of Glycolytic and Mitochondrial Metabolism by Ras. Curr Pharm Biotechnol 2012, [Epub ahead of print].
7. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010, 107:8788-8793. 10.1073/pnas.1003428107, 2889315, 20421486.
8. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009, 8:41. 10.1186/1476-4598-8-41, 2717907, 19558692.
9. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prev 2000, 24:1-12.
10. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, et al. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res 2009, 15:1593-1600. 10.1158/1078-0432.CCR-08-2439, 19223492.
11. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010, 31:29-59. 10.1016/j.mam.2009.12.006, 20026172.
12. Gibson BW. The human mitochondrial proteome: oxidative stress, protein modifications and oxidative phosphorylation. Int J Biochem Cell Biol 2005, 37:927-934. 10.1016/j.biocel.2004.11.013, 15743667.
13. Kadenbach B, Huttemann M, Arnold S, Lee I, Bender E. Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic Biol Med 2000, 29:211-221. 10.1016/S0891-5849(00)00305-1, 11035249.
14. Kadenbach B, Merle P. On the function of multiple subunits of cytochrome c oxidase from higher eukaryotes. FEBS Lett 1981, 135:1-11. 10.1016/0014-5793(81)80932-5, 6274682.
15. Brookes PS, Levonen AL, Shiva S, Sarti P, Darley-Usmar VM. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med 2002, 33:755-764. 10.1016/S0891-5849(02)00901-2, 12208364.
16. Capaldi RA. Structure and function of cytochrome c oxidase. Annu Rev Biochem 1990, 59:569-596. 10.1146/annurev.bi.59.070190.003033, 2165384.
17. Kadenbach B, Jarausch J, Hartmann R, Merle P. Separation of mammalian cytochrome c oxidase into 13 polypeptides by a sodium dodecyl sulfate-gel electrophoretic procedure. Anal Biochem 1983, 129:517-521. 10.1016/0003-2697(83)90586-9, 6303162.
18. Anderson WF, Ohlendorf DH, Takeda Y, Matthews BW. Structure of the cro repressor from bacteriophage lambda and its interaction with DNA. Nature 1981, 290:754-758. 10.1038/290754a0, 6452580.
19. Capaldi RA, Marusich MF, Taanman JW. Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. Methods Enzymol 1995, 260:117-132.
20. Campian JL, Gao X, Qian M, Eaton JW. Cytochrome C oxidase activity and oxygen tolerance. J Biol Chem 2007, 282:12430-12438. 10.1074/jbc.M604547200, 17303578.
21. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003, 3:1801-1810. 10.1002/pmic.200300461, 12973739.
22. Soejima K, Fang W, Rollins BJ. DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 2003, 22:4723-4733. 10.1038/sj.onc.1206510, 12879017.
23. Srivastava SK, Yuasa Y, Reynolds SH, Aaronson SA. Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci U S A 1985, 82:38-42. 10.1073/pnas.82.1.38, 396966, 3918304.
24. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004, 23:3172-3179. 10.1038/sj.onc.1207549, 15094766.
25. Lee S, Kang J, Cho M, Seo E, Choi H, Kim E, Kim J, Kim H, Kang GY, Kim KP, et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009, 34:161-172.
26. Dejean L, Beauvoit B, Bunoust O, Guerin B, Rigoulet M. Activation of Ras cascade increases the mitochondrial enzyme content of respiratory competent yeast. Biochem Biophys Res Commun 2002, 293:1383-1388. 10.1016/S0006-291X(02)00391-1, 12054668.
27. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signalling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064. 2518074, 18725989.
28. Horimoto M, Resnick MB, Konkin TA, Routhier J, Wands JR, Baffy G. Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res 2004, 10:6203-6207. 10.1158/1078-0432.CCR-04-0419, 15448008.
29. Lorenzo M, Valverde AM, Teruel T, Alvarez A, Benito M. p21ras induced differentiation-related gene expression in fetal brown adipocyte primary cells and cell lines. Cell Growth Differ 1996, 7:1251-1259.
30. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One 2009, 4:e7033. 10.1371/journal.pone.0007033, 2737639, 19753307.
31. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987, 71:297-304.